Clinical Trial Update: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

View source ↗

Summary

A clinical trial investigating aflibercept 8 mg for neovascular age-related macular degeneration and diabetic macular edema in real-world settings has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Eylea) (aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD) | Status: WITHDRAWN